Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023Подробнее

PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myelomaПодробнее

Early results of PHE885, a novel BCMA-directed CAR-T therapy for the treatment of R/R MMПодробнее

Phase I study of CART-ddBCMA in R/R multiple myelomaПодробнее

Phase I study of PHE885 CAR T-cell therapy in R/R multiple myelomaПодробнее

Blood Cancer Research: CAR-T in Multiple MyelomaПодробнее

PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myelomaПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1Подробнее

Phase 1 Study of CAR T-ddBCMA in RRMM Presented at ASCO 2022Подробнее

Phase 1 Clinical Study of the BCMA Nex T CAR T Cell Therapy CC-98633/BMS-986354 in pts with RRMMПодробнее

Yi Lin, MD, PhD, on how anti-BCMA CAR-T cell therapy fits into the treatment of RRMMПодробнее

Challenges associated with the use of off-the-shelf CAR-T products in multiple myelomaПодробнее

Novel CAR-T constructs being explored in myeloma: T-Charge platformПодробнее

Q&A | How to sequence CAR T-cell therapy and bispecific antibodies in R/R MMПодробнее

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r mu...Подробнее

GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)Подробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее